Feedback
Nicotine and Metabolites, Urine, Quantitative
0092356
Ordering Recommendation
Assess active exposure to nicotine and compliance with smoking-cessation programs. Use to confirm cotinine screening results.
Mnemonic
NICOTINEUR
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-4 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
  
Collect
Random urine.  
Specimen Preparation
Transfer 4 mL with no additives or preservatives urine to an ARUP Standard Transport Tube. (Min: 1 mL)  
Storage/Transport Temperature
Room temperature.  
Unacceptable Conditions
Specimens exposed to repeated freeze/thaw cycles.  
Remarks
  
Stability
Ambient: 10 days; Refrigerated: 10 days; Frozen: 8 months  
Reference Interval
Effective August 17, 2015
 
Drugs Covered Cutoff Concentrations
Nicotine 2 ng/mL
Cotinine (metabolite) 5 ng/mL
3-​OH-​Cotinine (metabolite) 50 ng/mL
Nornicotine (metabolite) 2 ng/mL
Anabasine (tobacco biomarker) 3 ng/mL
Interpretive Data
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry

Positive cutoff
:
Nicotine 2 ng/mL
Cotinine 5 ng/mL
3-OH-Cotinine 50 ng/mL
Nornicotine 2 ng/mL
Anabasine 3 ng/mL

For medical purposes only; not valid for forensic use.

This test is designed to evaluate recent use of nicotine-containing products. Passive and active exposure cannot be discriminated definitively, although a cutoff of 100 ng/mL cotinine is frequently used for surgery qualification purposes. For smoking cessation programs or compliance testing, the absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Anabasine is included as a biomarker of tobacco use, versus nicotine replacement. Interpretive questions should be directed to the laboratory.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
80323; (Alt code: G6055)
Components
Component Test Code*Component Chart NameLOINC
0092357Nicotine, Urn, Quant3854-7
0092358Cotinine, Urn, Quant10366-3
00923593-OH-Cotinine, Urn, Quant33916-8
0092360Nornicotine, Urn, Quant33917-6
0092365Anabasine, Urn, Quant33915-0
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • 3-Hydroxycotinine
  • Anabasine
  • Cotinine
  • Nicotine and Cotinine, LC/MS/MS, Urine
  • Nornicotine
  • Pain Management